Randy A. Hall

Curriculum vitae Contact Information Department of Pharmacology Emory University School of Medicine Rollins Research Center, Room 5113 1510 Clifton Rd. Atlanta, GA 30322 Phone: 404-727-3699 Fax: 404-727-0365 E-mail: rhall3@emory.edu Lab website: http://www.pharm.emory.edu/rhall ORCID: http://orcid.org/0000-0002-8318-8728 Personal Born in Nashua, NH, September 3rd, 1968 Married to Liberty Ann Hall; 2 daughters, Violet Ann Hall (b. 2011) & Ruby Mae Hall (b. 2015) Education 1990 B.S. (Biochemistry) University of New Hampshire (Mentor: Richard Cote) 1994 Ph.D. (Neurobiology) University of California, Irvine (Mentor: Gary Lynch) Postgraduate Training 1994-1996 Post-doctoral fellow, Vollum Institute, Oregon Health Sciences University (Mentor: Thomas Soderling) 1996-1999 Post-doctoral fellow, Howard Hughes Medical Institute, Duke University Medical Center (Mentor: Robert Lefkowitz) Academic Positions 1999-2005 Assistant Professor, Emory University School of Medicine 2005-2011 Associate Professor, Emory University School of Medicine 2011-present Professor, Emory University School of Medicine

Committee Memberships National & International NSF, Faculty Early Career Development study section (ad-hoc), 2005 NIH, Mol. Neuropharm. & Signaling (MNPS) study section (ad-hoc), 2005-2006 NIH, NIGMS Minority Biomedical Research (MBRS) study section (ad-hoc), 2007 NSF, Molecular and Cellular Biosciences (MCB) study section (ad-hoc), 2008 NIH, Cell Biology IRG Special Emphasis Panel study section (ad-hoc), 2008-2010 Executive Committee, Molecular Pharmacology Division, American Society for Pharmacology

and Experimental Therapeutics (ASPET), 2008-2014 Wellcome Trust (U.K.), Neuroscience & Mental Health review board (ad-hoc), 2009 Medical Research Council (U.K.), Population & Systems Medicine Board (ad-hoc), 2009 ASPET Awards Committee, 2009-2012 M.J. Murdock Charitable Trust, grant reviewer (ad-hoc), 2009, 2011 ASPET Board of Publications Trustees, 2009-2015 Netherlands Organisation for Scientific Research, grant reviewer (ad-hoc), 2010 Chair, Executive Committee, Molecular Pharmacology Division, ASPET, 2011-2012 Julius Axelrod Award Committee, ASPET, 2011-2016 NIH, Molecular Neuroscience IRG Special Emphasis Panel study section (ad-hoc), 2011 ASPET Program Committee, 2012-2014 Swiss National Science Foundation, grant reviewer (ad-hoc), 2013 Carver Trust, grant reviewer (ad hoc), 2015 NIH, Molecular & Integrative Signal Transduction (MIST) study section (ad-hoc), 2015-2016 ASPET Symposium on Adhesion GPCRs, Co-Chair, 2016 Regional Executive Committee, Atlanta Chapter of the Society for Neuroscience, 2001-2004

Institutional Executive Committee, Emory Molecular & Systems Pharmacology (MSP) graduate program,

2004-present Director of Recruiting, Emory MSP graduate program, 2004-2008 Curriculum Committee, Emory Graduate Division of Biological & Biomedical Sciences

(GDBBS), 2008 Curriculum Advising Committee, Molecular & Systems Pharmacology Program, 2008-2010 Steering Committee, Emory NIDA training grant, 2010-2014 Woodruff Fellowship Selection Committee, 2010-2012 GDBBS Executive Committee, 2010-present Director, Emory MSP graduate program, 2010-present Neuroscience Program Faculty Membership Committee, 2015-present Editorships and Editorial Boards Editorial Board, Molecular Interventions, 2005-2010 Editorial Board, Molecular Pharmacology, 2009-present Editorial Board, EMBO Journal, 2011-present

Manuscript Reviewer Advances in Pharmacology --- American Journal of Physiology --- Biochemistry Biochimica et Biophysica Acta --- Biotechniques --- Brain Research British Journal of Pharmacology --- Cancer Research --- ChemBioChem Cell Adhesion & Migration --- Cellular & Molecular Life Sciences --- Chemistry & Biology Current Drug Targets --- Drug Discovery Today --- EMBO Journal --- EMBO Reports European Journal of Neuroscience --- Experimental Cell Research --- Experimental Neurology FASEB Journal --- FEBS Letters --- FEBS Journal --- Journal of Biological Chemistry Journal of Cell Science --- Journal of Molecular Biology --- Journal of Neurochemistry Journal of Neuroscience --- Journal of Neuroscience Research Journal of Pharmacology & Experimental Therapeutics --- Molecular Interventions Molecular & Cellular Biology --- Molecular & Cellular Neuroscience Molecular Biology of the Cell --- Molecular Pharmacology --- Nature --- Nature Protocols --- Nature Communications --- Neuropharmacology --- Neuroscience --- Neuroscience Letters Neurotoxicity --- Oncogene --- Pharmacological Reviews --- PLoS Biology --- PLoS One Protein Science --- Proceedings of the National Academy of Sciences USA --- Science Signaling Synapse --- Traffic --- Trends in Biochemical Sciences --- Trends in Neurosciences Trends in Pharmacological Sciences Honors and Awards Post-Doctoral Fellowship, Howard Hughes Medical Institute, 1996 Faculty Development Award, Pharmaceutical Research and Manufacturers of America

(PhRMA) Foundation, 2000 Teaching Excellence Award, Emory University Department of Pharmacology, 2002 Distinguished Young Scholar in Medical Research Award, W.M. Keck Foundation, 2002 Dean’s Teaching Award, Emory University School of Medicine, 2004 John J. Abel Award in Pharmacology, American Society for Pharmacology and

Experimental Therapeutics, 2005 Teaching Excellence Award, Emory University Department of Pharmacology, 2007 Fellow of the American Association for the Advancement of Science (AAAS), 2014 Society Memberships American Association for the Advancement of Science (1990-present) American Society for Pharmacology and Experimental Therapeutics (1999-present) Society for Neuroscience (1990-present) Research Focus My laboratory’s research is focused on the mechanisms of signal transduction by hormone and neurotransmitter receptors. In particular, we study receptor/scaffold and receptor/receptor interactions, which can profoundly regulate receptor activity, pharmacology, and cellular trafficking. These studies are of significant clinical importance because hormone and neurotransmitter receptors are extremely common targets for therapeutic pharmaceuticals.

Grant Support Active Grants: “GPR37 & GPR37L1 signaling pathways promoting cell survival: relevance to stroke” Principal Investigator: Randy A. Hall Co-Investigator: Shan Ping Yu Agency: NIH Type: R01 Number: NS088413 Period: 7/01/14 – 6/30/19 Total direct costs: $1,071,875 Summary: In this project, we will study the brain-expressed receptors GPR37 and GPR37L1,

which are activated by a ligand (prosaposin) known to exert protective effects following stroke. In both cultured cells and a mouse model of stroke in vivo, we will assess the protective actions of these receptors and the relevant downstream signaling pathways. These studies will provide insights into the potential utility of GPR37 & GPR37L1 as novel targets for the treatment of stroke and also shed light on the signaling pathways downstream of these receptors that mediate their protective effects.

“BAI2 mutation associated with a novel neurological disorder” Principal Investigator: Randy A. Hall Agency: NIH Type: R21 Number: R21-NS094136 Period: 4/01/15 – 3/31/17 Total direct costs: $275,000 Summary: This project is focused on studying a mutation in the G protein-coupled receptor

BAI2 that is associated with a novel inherited neurological disorder characterized by spinal cord atrophy, abnormal sensory-evoked potentials and progressive spastic quadriparesis. We will assess the effects of the mutation on the folding, trafficking and signaling of BAI2 in order to determine how this mutation may be causing human disease.

“GPR37L1 mutation associated with a novel neurological disorder” Principal Investigator: Randy A. Hall Agency: NIH Type: R21 Number: R21-NS091986 Period: 6/01/15 – 5/31/17 Total direct costs: $275,000 Summary: This project is focused on studying a mutation in the G protein-coupled receptor

GPR37L1 that is associated with a novel inherited neurological disorder characterized by progressive seizures starting around puberty and resulting in death before adulthood. We will assess the effects of the mutation on the folding, trafficking and signaling of GPR37L1 in order to determine how this mutation may be causing human disease and how patients harboring this mutation might be treated.

“Graduate Training in the Pharmacological Sciences” Principal Investigator: Randy A. Hall Agency: NIH Type: T32 Number: GM008602 Period: 7/1/2012 – 6/30/2017 Total direct costs: $1,275,960 Summary: Modern drug discovery and development require the training of scientists who

understand the molecular, physiological and quantitative basis of drug action and specificity, and who can apply modern technologies and concepts to the development of novel therapeutic strategies. This multidisciplinary doctoral training program in the Pharmacological Sciences is designed to help meet that demand by preparing students for

biomedical research careers in schools of medicine, dentistry and pharmacy, in research institutes, and in governmental or industrial laboratories.

Completed Projects: “Activation and regulation of the neural stem cell-expressed receptor GPR56” Principal Investigator: Randy A. Hall Agency: NIH Type: R01 Number: NS072394 Period: 6/01/11 – 2/29/16 Total direct costs: $1,093,750 Summary: Neural stem cells give rise to new neurons and glia in the brain throughout development and adulthood, and modulation of neural stem cells is a promising therapeutic approach in the treatment of a number of neurodevelopmental and neurodegenerative disorders. GPR56 is an orphan G protein-coupled receptor GPR56 that is highly-expressed in neural stems cells during development and in the subventricular zone in adult brains but absent from mature neurons and glia. The goal of this work was to understand the activation and regulation of GPR56, since this receptor is an attractive target for therapeutics that might be capable of highly-selective modulation of neural stem cells. “Targeting the oligodendrocyte-enriched receptors GPR37 & GPR37L1 to treat multiple sclerosis” Principal Investigator: Randy A. Hall Agency: National Multiple Sclerosis Society Type: Fast Forward program Total direct costs: $471,333 Period: 10/1/13 – 3/31/15 Summary: This project assessed whether the orphan G protein-coupled receptors GPR37 and GPR37L1 mediate the protective effects of prosaptide on cultured oligodendrocytes and also screened for small molecules with drug-like properties that can mimic or enhance the

ability of prosaptide to activate GPR37 and/or GPR37L1. “Activation of GPR37 and GPR37L1 by prosaptide, a neuroprotective peptide” Principal Investigator: Randy A. Hall Agency: NIH Type: R21 Number: NS081461 Period: 9/24/12 – 8/31/14 Total direct costs: $275,000 Summary: The studies described in this proposal assessed whether the orphan G protein- coupled receptors GPR37 and GPR37L1 mediate the physiological effects of prosaptide on cultured cells known to be responsive to prosaptide stimulation. "PDZ scaffold regulation of astrocytic glutamate receptors and transporters" Principal Investigator: Randy A. Hall Agency: NIH Type: R01 Number: NS055179 Period: 2/1/08 - 1/31/13 Total direct costs: $984,375 Summary: The goals of this work were to examine NHERF regulation of mGluR3, mGluR5 and EAAT1 functional activity and cross-talk in astrocytes, and explore the possibility that NHERF scaffold proteins may control mGluR and EAAT1 localization in vivo by performing immunohistochemical analyses on brain tissue from wild-type versus NHERF knockout mice.

“Fundamental mechanisms of GPR56 activation and regulation” Principal Investigator: Randy A. Hall Agency: NIH Type: R21 Number: NS063029 Period: 1/15/09 - 12/31/10 Total direct costs: $175,000 Summary: The goal of this work was to study the fundamental properties of the orphan receptor GPR56, which is believed to play a key role in cortical development since GPR56 mutations cause a rare genetic disorder in which the development of the cerebral cortex is grossly distorted. Specifically, we shed light on the mechanism of receptor activation as well as the regulation of GPR56 signaling by kinases, arrestins and PDZ scaffolds. "Functional interactions between GABAA and GABAB receptors" Principal Investigator: Randy A. Hall Agency: NIH Type: RO1 Number: NS45644 Period: 2/1/03-1/31/08 Total direct costs: $830,000 Summary: The goals of this work were to characterize the structural determinants of the interaction between GABAA and GABAB receptors, to determine the functional importance of this interaction, and to determine where in the brain the receptors co-localize and associate. "Heptahelical receptor combinations: novel targets for therapeutics" Principal Investigator: Randy A. Hall Agency: W.M. Keck Foundation Type: Distinguished Young Scholar Award Period: 7/01/02 - 6/30/07 Total direct costs: $1,000,000 Summary: The major goals of this work were to study heterodimerization between neurotransmitter receptors and determine whether particular heteromeric combinations of receptors might represent novel targets for therapeutic pharmaceuticals “C-terminal interactions of α1-adrenoceptor subtypes” Principal Investigator: Kenneth P. Minneman Co-investigator: Randy A. Hall Agency: NIH Type: R01 Number: NS21325 Period: 07/01/00 - 06/30/04 Total direct costs: $700,000 Summary: The major goals of this project were to characterize intracellular binding partners for α1A, α1B, and α1D-AR C-terminal tails and examine the functional roles of these interactions in regulating α1-AR signaling and trafficking. "The role of NHERF in β2-adrenergic receptor signaling" Principal Investigator: Randy A. Hall Agency: NIH Type: RO1 Number: HL64713 Period: 4/10/00-3/31/04 Total direct costs: $725,000 Summary: The focus of this work was to elucidate the ways in which β2-adrenergic receptors can influence intracellular signaling pathways via agonist-promoted coupling to the Na+/H+ exchanger regulatory factor (NHERF).

"β1-adrenergic receptor regulation by PDZ scaffolds" Principal Investigator: Randy A. Hall Agency: NIH Type: RO1 Number: GM60982 Period: 3/1/00-2/28/05 Total direct costs: $700,000 Summary : The goals of this work were to characterize the interactions of β1-adrenergic receptors with intracellular PDZ scaffold proteins and to understand the physiological significance of these interactions for β1-adrenergic receptor signaling and regulation. Formal Teaching Medical Student Teaching IBS 716/MEDI 640: General Medical Pharmacology 4 lectures annually (2000-2016) Graduate Student Teaching IBS 514: Molecular and Cellular Neuroscience 3 lectures annually (2000-2016) IBS 531/2: Principles of Pharmacology 5 lectures annually (2000-2016) IBS 556: Principles of Basic Biomedical Sciences 3 lectures annually (2004-2011) NS 559: Techniques in Neuroscience 1 lecture annually (2006-2014) IBS 570: Molecular & Systems Pharmacology Seminar course director (2001-2003) IBS 701: Cell Surface Receptors 2 lectures (2001-2016, alternate years) IBS 702: Mechanisms of Signal Transduction 2 lectures (2000-2010, alternate years) Physician Assistant Student Teaching IBS 532/BAHS 504: Allied Health Pharmacology 3 lectures annually (2000-2016) Supervisory Teaching Ph.D. Students Directly Supervised 1. Maryse Paquet (Ph.D., Neuroscience program, 2006) Current position: Clinical Trial Coordinator, Mediprobe Research (London, Ontario) 2. Masaaki Kuwajima (Ph.D., Neuroscience program, 2006) Current position: Research Associate, University of Texas at Austin (laboratory of Kristen Harris) 3. Srividya Balasubramanian (Ph.D., Molecular & Systems Pharmacology program, 2006)

Current position: Scientist II at Constellation Pharmaceuticals (Boston, MA) 4. Cristina Bush Germond (Ph.D., Molecular & Systems Pharmacology Program, 2008) Current position: Medical Writer, Science Delivery LLC (Cary, NC) 5. Jill Dunham (Ph.D., Molecular & Systems Pharmacology Program, 2009) Current position: Senior Content Development Specialist, Pharmaceutical Institute (Raleigh, NC) 6. Kevin Paavola (Ph.D., Molecular & Systems Pharmacology Program, 2012) Current position: Post-doctoral fellow, NGM Biopharmaceuticals (San Francisco, CA)

7. Stefanie Ritter (Ph.D. Neuroscience Program, 2013) Current position: Post-doctoral fellow, Gladstone Institute, UCSF (laboratory of Jeanne Paz) 8. Jason Stephenson (Ph.D., Molecular & Systems Pharmacology Program, 2013) Current position: Post-doctoral fellow, Vanderbilt University (laboratory of Roger Colbran) 9. Rebecca Meyer (Ph.D., Neuroscience Program, 2013) Current position: Post-doctoral fellow, Harvard Medical School (laboratory of John Flanagan) 10. Ayush Kishore (Molecular & Systems Pharmacology Program, 2011-present) 11. Michelle Giddens (Neuroscience Program, 2011-present) 12. Ryan Purcell (Neuroscience Program, 2012-present) 13. Brilee Coleman (Molecular & Systems Pharmacology Program, 2012-present) 14. TrangKimberly Nguyen (Molecular & Systems Pharmacology Program, 2016-present) Post-Doctoral Fellows Directly Supervised 1. Junqi He, PhD. (2000-2004) Current position: Professor, Capital University of Medical Sciences, Beijing 2. Jianguo Xu, Ph.D. (2000-2003)

Current position: Instructor, Emory University Dept. of Medicine 3. Jeremy Teissere, Ph.D. (2001-2003)

Current position: Associate Professor, Muhlenberg College Dept. of Biology 4. Michelle Uberti, Ph.D. (2003-2004) Current position: Medical Writer, ETHOS Health Communications (Newtown, PA) 5. Steven Prinster, Ph.D. (2003-2006)

Current position: Assistant Professor, Touro University College of Medicine (Nevada) 6. Sami Fam, Ph.D. (2003-2006)

Current position: Project Manager, Decision Resources Inc. (Waltham, MA) 7. Tomas Holmqvist, Ph.D. (2004-2006)

Current position: Group Leader, Actavis Inc. (Oslo, Norway) 8. Hiroyuki Inuzuka, Ph.D. (2004-2006) Current position: Instructor, Beth Israel Med. Ctr., Harvard Medical School 9. Matthew Asay, Ph.D. (2004-2007) Current position: Director of Health Physics, University of Utah 10. Sorin Tunaru, Ph.D. (2006-2008) Current position: Group Leader, Max Planck Institute (Frankfurt, Germany) 11. Sharon Owino, Ph.D. (2016-present) Undergraduate Students Directly Supervised: 1. Alex Quan (1992-1994)

Current position: Physician (Internal Medicine), Redlands, CA 2. Jeremy Blitzer (1997-1999) Current position: CEO, PharmaCon (San Francisco, CA) 3. Asha Shah (2003-2005)

Current position: Physician (Primary Care), Gwinnett Clinic, Gwinnett, GA

4. Rachel Reiff (2008-2012) Current position: MD/PhD program, Harvard Medical School 5. Ariella Iancu (2012-2015) Current position: Teach for America 6. Max Ward (2013-2016)

Current position: Medical school, Rutgers New Jersey Medical School 7. Paran Davari (2014, summer student in SIRE program)

Current position: Medical school, University of Kentucky School of Medicine 8. Zahra Nassiri-Toosi (2014-2015)

Current position: PhD program in Biology, Georgia Institute of Technology 9. Josephine Mak (2015-2016)

Current position: MPH program, Emory University School of Public Health 10. Anqi Gao (2014-present) 11. Jessie Jiang (2016-present) Membership on Ph.D. Thesis Committees 1. Valerie Horsley (Ph.D., Biochemistry, Cell and Developmental Biology program, 2003) 2. Alick Law (Ph.D., Neuroscience program, 2003) 3. Susanne Hollinger (Ph.D., Neuroscience program, 2003) 4. Daniel McClatchey (Ph.D., Neuroscience program, 2004) 5. Kevin Eggreger (Ph.D., Neuroscience program, 2004) 6. Diana Caracino (Ph.D., Genetics and Molecular Biology program, 2005) 7. Ricardo Caceda (Ph.D., Neuroscience program, 2005) 8. Dinesh Raju (M.D./Ph.D., Neuroscience program, 2005) 9. Zhongjian Chen (Ph.D., Molecular and Systems Pharmacology program, 2006) 10. Juan Rong (Ph.D., Neuroscience program, 2006) 11. Gavin Porter (Ph.D., Molecular and Systems Pharmacology program, 2006) 12. Karen Rommelfanger (Ph.D., Neuroscience program, 2007) 13. William Michael Caudle (Ph.D., Neuroscience program, 2007) 14. Katherine Hubbard Pedone (Ph.D., Molecular and Systems Pharmacology program, 2007) 15. Jill Bordelon (Ph.D., Neuroscience program, 2008) 16. Darlene Mitrano (Ph.D., Molecular and Systems Pharmacology program, 2008) 17. Jesse Schank (Ph.D., Neuroscience program, 2008) 18. Li-Ting Chien (Ph.D., Neuroscience program, 2008) 19. Anna Orr (Ph.D., Neuroscience program, 2008) 20. Liliya Iskhakova (Ph.D., Neuroscience program, 2009) 21. Chad Kitchen (Ph.D., Molecular and Systems Pharmacology program, 2009) 22. Albert “Gus” Davis (M.D./Ph.D., Neuroscience program, 2009) 23. Hasan Irier (Ph.D., Molecular and Systems Pharmacology program, 2009) 24. George Rogge (Ph.D., Molecular and Systems Pharmacology program, 2010) 25. Kelly McCoy (Ph.D., Molecular and Systems Pharmacology program, 2010) 26. Kimberly Maguschak (Ph.D., Neuroscience Program, 2010) 27. Chad Jackson (Ph.D., Molecular and Systems Pharmacology program, 2010) 28. Heather Mitchell (Ph.D., Molecular and Systems Pharmacology program, 2010) 29. Meagan Jenkins (Ph.D., Neuroscience Program, 2011)

30. Danielle Dean (Ph.D., Molecular and Systems Pharmacology program, 2011) 31. Sarah Cork (Ph.D., Neuroscience Program, 2011) 32. Amy Mahan (Ph.D., Neuroscience program, 2011) 33. Andrea Liatis (Ph.D., Neuroscience Program, 2011) 34. Kristen Cincotta (Ph.D., Neuroscience Program, 2011) 35. Stacey Dutton (Ph.D., Neuroscience Program, 2011) 36. Shareen Iqbal (Ph.D., Neuroscience Program, 2012) 37. Christopher Vellano (Ph.D., Molecular and Systems Pharmacology program, 2012) 38. Meera Modi (Ph.D., Neuroscience Program, 2012) 39. Sarah Emerson Lee (Ph.D., Molecular and Systems Pharmacology program, 2012) 40. Sharon Swanger (Ph.D., Neuroscience Program, 2012) 41. Jim Bogenpohl (Ph.D., Neuroscience program, 2012)

42. Tim Acker (Ph.D., Molecular and Systems Pharmacology program, 2013) 43. Sara Freeman (Ph.D., Neuroscience program, 2013) 44. Ana Monteiro (M.D./Ph.D., Biochemistry, Cell & Dev. Biology program, 2013) 45. Ebba Lundius (Ph.D., Karolinska Institute – served as opponent, 2013) 46. Ahmad Sylvester (Ph.D., Neuroscience Program, 2014) 47. Mallory Bowers (Ph.D., Neuroscience program, 2014) 48. Laura Mariani (Ph.D., Neuroscience program, 2015) 49. Paul Evans (Ph.D., Neuroscience program, 2016) 50. Jessica Eliason (Ph.D. candidate, Genetics & Molecular Biology program) 51. Brandon Stauffer (Ph.D. candidate, Molecular and Systems Pharmacology program) 52. Daniel Curry (Ph.D. candidate, Neuroscience program) 53. Lauren Shapiro (Ph.D. candidate, Molecular and Systems Pharmacology program) 54. Iris Spiegel (Ph.D. candidate, Neuroscience program) 55. Katherine Squires (Ph.D. candidate, Molecular and Systems Pharmacology program) 56. Chao Lin (Ph.D. candidate, Neuroscience program) 57. Kyle Gerber (Ph.D. candidate, Molecular and Systems Pharmacology program) 58. Byron Gardner (Ph.D. candidate, Neuroscience program)

Invited Seminars 1. April 1998 Harvard Medical School Dept. of Psychiatry/McLean Hospital 2. June 1998 Emory University Dept. of Pharmacology 3. May 2000 GPCR 2K meeting San Diego, CA 4. October 2001 Great Lakes GPCR Retreat Bromont, Québec 5. April 2002 W.M. Keck Foundation meeting Los Angeles, CA 6. December 2002 Mercer University Dept. of Medicine 7. March 2003 Vanderbilt University Dept. of Pharmacology 8. March 2004 Medical College of Georgia Dept. of Pharm. & Tox. 9. March 2004 University of Tennessee, Memphis Dept. of Pharmacology 10. June 2004 University of Montreal Dept. of Pharmacology 11. October 2004 Georgia Institute of Technology Dept. of Biology 12. February 2005 Johns Hopkins University Dept. of Biological Chemistry 13. June 2005 Gordon Research Conference Biddeford, ME 14. March 2007 University of Pittsburgh Dept. of Pharmacology 15. March 2007 University of Michigan Center for Chemical Genomics 16. March 2007 University of Vermont Dept. of Pharmacology 17. April 2007 ASPET meeting Washington, DC 18. July 2008 ISOT meeting San Francisco, CA 19. March 2009 University of California, San Diego Dept. of Pharmacology 20. April 2009 LSU Health Sciences Center Dept. of Pharmacology 21. April 2009 Berry College Dept. of Biology 22. June 2009 Gordon Research Conference Biddeford, ME 23. June 2010 Scripps Research Institute, Florida Dept. of Molecular Therapeutics 24. October 2010 University of Texas, Houston Dept. of Integrat. Biol. & Pharmacol. 25. April 2011 W.M. Keck Foundation meeting Irvine, CA 26. March 2012 U. Alabama Birmingham Dept. of Physiology & Biophysics 27. March 2012 Oregon Health Sciences Univ. Vollum Institute 28. June 2012 Endocrine Society meeting Houston, TX 29. October 2012 Great Lakes GPCR Retreat London, Ontario 30. January 2013 American Chem. Society meeting Chattanooga, TN 31. December 2013 Karolinska Institute Stockholm, Sweden 32. June 2014 Adhesion GPCR Workshop Boston, MA 33. November 2014 Auburn University Dept. Drug Discovery & Development 34. February 2015 Gordon Research Conference Ventura, CA 35. March 2015 University of Georgia Dept. of Physiology & Pharmacology 36. May 2015 University of Rochester Dept. of Pharmacology & Physiology 37. October 2015 Great Lakes GPCR Retreat Toronto, Ontario 38. April 2016 ASPET meeting San Diego, CA 39. June 2016 Adhesion GPCR Workshop Leipzig, Germany

Bibliography (114 total articles published in peer-reviewed journals; 93 research articles & 21 review articles) Published Research Articles 1. Bahr B.A., Vodyanoy V., Hall R.A., Suppiramaniam V., Kessler M., Sumikawa K. and Lynch G. (1992) Functional reconstitution of alpha-amino-3-hydroxy-5-methylisoxazole-4- propionic acid (AMPA) receptors from rat brain. J. Neurochem. 59, 1979-1982. 2. Hall R.A., Kessler M. and Lynch G. (1992) Evidence that high- and low-affinity DL-alpha- amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) binding sites reflect membrane-dependent states of a single receptor. J. Neurochem. 59, 1997-2004. 3. Bahr B.A., Godshall A.C., Hall R.A. and Lynch G. (1992) Mouse telencephalon exhibits an age-related decrease in glutamate (AMPA) receptors but no change in nerve terminal

markers. Brain Res. 589, 320-326. 4. Vodyanoy V., Bahr B.A., Suppiramaniam V., Hall R.A., Baudry M. and Lynch G. (1993) Single channel recordings of reconstituted AMPA receptors reveal low and high

conductance states. Neurosci. Lett. 150, 80-84. 5. Hall R.A., Massicotte G., Kessler M., Baudry M. and Lynch G. (1993) Thiocyanate equally increases affinity for two AMPA receptor states. Mol. Pharmacol. 43, 459-464. 6. Hall R.A., Kessler M., Quan A., Ambros-Ingerson J. and Lynch G. (1993) Cyclothiazide decreases [3H]AMPA binding to rat brain membranes: Evidence that AMPA receptor desensitization increases agonist affinity. Brain Res. 628, 345-348.

7. Larson J., Le T., Hall R.A. and Lynch G. (1994) Effects of cyclothiazide on synaptic responses in slices of adult and neonatal hippocampus. Neuroreport 5, 389-392.

8. Hall R.A., Kessler M. and Lynch G. (1994) Kainate binding to the AMPA receptor in rat

brain. Neurochem. Res. 19, 777-782.

9. Hall R.A. and Bahr B.A. (1994) AMPA receptor development in rat telencephalon: [3H]AMPA binding and western blot studies. J. Neurochem. 63, 1658-1665.

10. Bahr B.A., Kessler M., Rivera S., Vanderklish P., Hall R.A., Mutneja M.S., Gall C. and

Hoffman K.B. (1995) Stable maintenance of glutamate receptors and other synaptic components in long-term hippocampal slices. Hippocampus 5, 425-439.

11. Hall R.A., Vodyanoy V., Quan A., Sinnarajah S., Suppiramaniam V., Kessler M. and

Bahr B.A. (1996) Effects of heparin on the properties of solubilized and reconstituted rat brain AMPA receptors. Neurosci. Lett. 217, 179-183.

12. Hall R.A., Quan A., Kessler M. and Lynch G. (1996) Ultraviolet radiation, thiol reagents, and solubilization enhance AMPA receptor binding affinity via a common mechanism. Neurochem. Res. 21, 969-974.

13. Bahr B.A., Hoffman K.B., Kessler M., Hennegriff M., Park G.Y., Yamamoto R.S., Kawasaki B.T., Vanderklish P.W., Hall R.A. and Lynch G. (1996) Distinct distributions of

AMPA receptor subunits and a related 53,000 MR antigen (GR53) in brain tissue. Neuroscience 74, 707-721.

14. Hall R.A. and Soderling T.R. (1997) Differential surface expression and phosphorylation of

the NMDA receptor subunits NR1 and NR2 in cultured hippocampal neurons. J. Biol. Chem. 272, 4135-4140.

15. Hall R.A., Hansen A., Andersen P.H. and Soderling T.R. (1997) Surface expression of

AMPA receptor subunits stably-expressed in kidney cells is dependent on receptor glycosylation state. J. Neurochem. 68, 625-630.

16. Hall R.A. and Soderling T.R. (1997) Quantitation of AMPA receptor surface expression in cultured hippocampal neurons. Neuroscience 78, 361-371. 17. Pitcher J.A., Hall R.A., Daaka Y., Zhang J., Ferguson S.S.G., Hester S., Miller S., Caron

M.G., Lefkowitz R.J. and Barak L. (1998) The G protein-coupled receptor kinase 2 is a microtubule-associated protein kinase that phosphorylates tubulin. J. Biol. Chem. 273,12316-12324.

18. Hall R.A., Premont R.T., Chow, C.-W., Blitzer J.T., Pitcher J.A., Claing A., Stoffel R.H.,

Barak L.S., Shenolikar S., Weinman E.J., Grinstein S. and Lefkowitz R.J. (1998) The β2-adrenergic receptor interacts with the Na+/H+ exchanger regulatory factor (NHERF) to control Na+/H+ exchange. Nature 392, 626-630.

19. Weinman E.J., Steplock D., Tate K., Hall R.A., Spurney R.F. and Shenolikar S. (1998)

Structure-function of recombinant Na/H exchanger regulatory factor (NHE-RF). J. Clin. Invest. 101, 2199-2206.

20. Snow B.E., Hall R.A., Krumins A., Brothers G.M., Bouchard D., Brothers C.A., Mangion

J., Chung S., Gilman A.G., Lefkowitz R.J. and Siderovski D.P. (1998) GTPase activating specificity of RGS12 and binding specificity of an alternatively-spliced PDZ domain. J. Biol. Chem. 273, 17749-17755.

21. Hall R.A., Ostedgaard L.S., Premont R.T., Blitzer J.T., Rahman N., Welsh M.J. and Lefkowitz R.J. (1998) A C-terminal motif found in the β2-adrenergic receptor, P2Y1 receptor and cystic fibrosis transmembrane conductance regulator determines binding to the Na+/H+ exchanger regulatory factor family of PDZ proteins. Proc. Natl. Acad. Sci. USA 95, 8496-8501.

22. Sinnarajah S., Suppiramaniam V., Kumar K.P., Hall R.A., Bahr B.A. and Vodyanoy V. (1999) Heparin modulates the single channel kinetics of reconstituted AMPA receptors from rat brain. Synapse 31, 203-209.

23. Hall R.A., Spurney R.F., Premont R.T., Rahman N., Blitzer J.T., Pitcher J.A. and Lefkowitz

R.J. (1999) G protein-coupled receptor kinase 6A phosphorylates the Na+/H+ exchanger regulatory factor (NHERF) via a PDZ domain-mediated interaction. J. Biol. Chem. 274, 24328-24334.

24. Tang Y., Hu L.A., Miller W.E., Ringstad N., Hall R.A., Pitcher J.A., DeCamilli P. and

Lefkowitz R.J. (1999) Identification of the endophilins (SH3p4/p8/p13) as novel binding partners for the β1-adrenergic receptor. Proc. Natl. Acad. Sci. USA 96, 12559-12564.

25. Maudsley S., Zamah A.M., Rahman N., Blitzer J.T., Luttrell L.M., Lefkowitz R.J and Hall R.A. (2000) PDGF receptor association with the Na+/H+ exchanger regulatory factor (NHERF) potentiates receptor activity. Mol. Cell Biol. 20, 8352-8363.

26. Kanai F., Marignani P.A., Sarbasova D., Yagi R., Hall R.A., Donowitz M., Hisaminato A., Fujiwara T., Carpenter C.L., Ito Y., Cantley, L.C. and Yaffe M.B. (2000) TAZ: a novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins. EMBO J. 19, 6778-6791.

27. Hu L.A., Tang Y., Miller W.E., Cong M., Lau A.G., Lefkowitz R.J. and Hall R.A. (2000) β1-adrenergic receptor association with PSD-95: inhibition of receptor internalization and facilitation of β1-adrenergic receptor interaction with NMDA receptors. J. Biol. Chem. 275, 38659-38666.

28. Lau A.G. and Hall R.A. (2001) Oligomerization of NHERF-1 and NHERF-2 PDZ domains:

differential regulation by association with receptor carboxyl-termini and by phosphorylation. Biochemistry 40, 8572-8580.

29. Xu J., Paquet M., Lau A.G., Wood J.D., Ross C.A. and Hall R.A. (2001) β1-adrenergic

receptor association with the synaptic scaffolding protein MAGI-2: differential regulation of receptor internalization by MAGI-2 and PSD-95. J. Biol. Chem. 276, 41310-41317.

30. He J., Lau A.G., Yaffe M.B. and Hall R.A. (2001) Phosphorylation and cell cycle-

dependent regulation of the Na+/H+ exchanger regulatory factor (NHERF-1) by cdc2 kinase. J. Biol. Chem. 276, 41559-41565.

31. Saugstad J.A., Yang S., Pohl J., Hall R.A., and Conn P.J. (2002) Interaction between

metabotropic glutamate receptor 7 and alpha tubulin. J. Neurochem. 80, 980-988.

32. McClatchey D.B., Knudson C.R., Clark B.F., Kahn R.A., Hall R.A. and Levey A.I. (2002) Novel interaction between the m4 muscarinic acetylcholine receptor and elongation factor 1A2. J. Biol. Chem. 277, 29268-29274.

33. He J., Xu J., Castleberry A.M., Lau A.G. and Hall R.A. (2002) Glycosylation regulates β1-adrenergic receptor surface expression and dimerization. Biochem. Biophys. Res. Comm. 297, 565-572.

34. Xu J., He J., Castleberry A.M., Balasubramanian S., Lau A.G. and Hall R.A. (2003)

Heterodimerization of α2A- and β1-adrenergic receptors. J. Biol. Chem. 278, 10770-10777. 35. He J., Xu J., Xu X.X. and Hall R. A. (2003) Cell cycle-dependent phosphorylation of

disabled-2 by cdc2. Oncogene 22, 4524-4530.

36. Uberti M.A., Hall R.A. and Minneman K.P. (2003) Subtype-specific dimerization of α1-adrenoceptor subtypes: effects on receptor expression and pharmacological properties. Mol. Pharmacol. 64, 1379-1390.

37. Hague C., Uberti M.A., Chen Z. Hall R.A. and Minneman K.P. (2004) Cell surface

expression of alpha1D-adrenergic receptors is controlled by heterodimerization with alpha1B-adrenergic receptors. J. Biol. Chem. 279, 15541-15549.

38. Balasubramanian S., Teissere J.A., Raju D.V. and Hall R.A. (2004) Hetero-oligomerization

between GABAA and GABAB receptors regulates GABAB receptor trafficking. J. Biol. Chem. 279, 18840-18850.

39. Kuwajima M., Hall R.A., Aiba A. and Smith Y. (2004) Subcellular and subsynaptic localization of group I metabotropic glutamate receptors in the monkey subthalamic nucleus. J. Comp. Neurol. 474, 589-602.

40. Huang P., Steplock D., Weinman E.J., Hall R.A., Ding Z., Wang Y., and Liu-Chen L.-Y.

(2004) Kappa opioid receptor interacts with NHERF-1/EBP50 to stimulate Na+/H+ exchange independent of Gi/Go proteins. J. Biol. Chem., 279, 25002-25009.

41. Charara A., Galvan A., Kuwajima M., Hall R.A. and Smith Y. (2004) An electron

microscope immunohistochemical study of GABABR2 receptors in the monkey basal ganglia: a comparative analysis with GABABR1 receptor distribution. J. Comp. Neurol., 476, 65-79.

42. Wang L., Kolachala V., Walia B., Balasubramanian S., Hall R.A., Merlin D. and Sitaraman

S.V. (2004) Agonist-induced polarized trafficking and surface expression of the adenosine 2b receptor in intestinal epithelial cells: role of SNARE proteins. Am. J. Physiol. (Gastrointest. Liver Physiol.) 287, G1100-1107.

43. Hague C., Uberti M.A., Chen Z., Bush C.F., Jones, S.V., Ressler K.J., Hall R.A. and

Minneman K.P. (2004) Olfactory receptor surface expression is driven by association with the β2-adrenergic receptor. Proc. Natl. Acad. Sci. USA 101, 13672-13676.

44. He J., Bellini M., Xu J., Castleberry A.M. and Hall R.A. (2004) Interaction with CAL

inhibits β1-adrenergic receptor surface expression. J. Biol. Chem. 279, 50190-50196.

45. Uberti M.A., Hague C., Oller H., Minneman K.P. and Hall R.A. (2005) Heterodimerization with β2-adrenergic receptors promotes surface expression and functional activity of α1D-adrenergic receptors. J. Pharmacol. Exp. Ther. 313, 16-23.

46. Yun C.C., Sun H., Wang D., Rusovic R., Castleberry A., Hall R.A. and Shim H. (2005)

The LPA2 receptor mediates mitogenic signals in human colon cancer cells. Am. J. Physiol. Cell Physiol., C2-C11.

47. Lakatos A., Vicentic A., Prinster S., Hall R.A. and Kuhar M.J. (2005) Cocaine and

amphetamine regulated transcript (CART) peptide activates the extracellular signal- regulated kinase (ERK) pathway in AtT20 cells via putative G protein coupled receptors. Neurosci. Lett. 384, 198-202.

48. Fam S.R., Paquet M., Castleberry A.M., Oller H., Lee C.J., Traynelis S.F., Smith Y., Yun

C.C. and Hall R.A. (2005) P2Y1 purinergic receptor signaling is controlled by interaction with the PDZ scaffold NHERF-2. Proc. Natl. Acad. Sci. USA 102, 8042-8047.

49. Paquet M., Kuwajima M., Yun C.C., Smith Y. and Hall R.A. (2006) Astrocytic and

neuronal localization of the scaffold protein NHERF-2 in mouse brain. J. Comp. Neurol., 494, 752-762.

50. Hague C., Lee S.E., Chen Z., Prinster S.C., Hall R.A. and Minneman K.P. (2006)

Heterodimers of α1B and α1D-adrenergic receptors form a single functional entity. Mol. Pharmacol. 69, 45-55.

51. He J., Bellini M., Inuzuka H., Xu J., Xiong Y., Wang X., Castleberry A.M. and Hall R. A.

(2006) Proteomic analysis of β1-adrenergic receptor interactions with PDZ scaffold proteins. J. Biol. Chem. 281, 2820-2827.

52. Villalba R.M., Raju D.V., Hall R.A. and Smith Y. (2006) GABA-B receptors in the

centromedian/parafascicular thalamic nuclear complex: an ultrastructural analysis of GABA-BR1 and GABA-BR2 in the monkey thalamus. J. Comp. Neurol. 496, 269-287.

53. Chen Z., Hague C., Hall R.A. and Minneman K.P. (2006) Syntrophins regulate α1D-

adrenergic receptors through a PDZ domain-mediated interaction. J. Biol. Chem. 281, 12414-12420.

54. Prinster S.C., Holmqvist T.G. and Hall R.A. (2006) Alpha-2C-adrenergic receptors exhibit

enhanced surface expression and signaling upon heterodimerization with beta-2-adrenergic receptors. J. Pharmacol. Exp. Ther. 318, 974-981.

55. Raju D.V., Shah D.J., Wright T.M., Hall R.A. and Smith Y. (2006) Differential synaptology

of vGluT2-containing thalamostriatal afferents between the patch and matrix compartments in rats. J. Comp. Neurol. 499, 231-243.

56. Paquet M., Asay M.J., Fam S.R., Inuzuka H., Castleberry A.M., Oller H., Smith Y., Yun C.C., Traynelis S.F. and Hall R.A. (2006) The PDZ scaffold NHERF-2 interacts with mGluR5 and regulates receptor activity. J. Biol. Chem. 281, 29949-29961.

57. Zhang H., Wang D., Sun H., Hall R.A. and Yun C.C. (2007) MAGI-3 regulates LPA-

induced activation of Erk and RhoA. Cell. Signalling 19, 261-268. 58. Fujii N., Shelat A., Novak K.A.P., Hall R.A. and Guy R.K. (2007) Design of a selective

chemical probe for Class 1 PDZ domains. Bioorganic Med. Chem. Lett. 17, 546-548. 59. Calin-Jageman I., Yu K., Hall R.A., Mei L. and Lee A. (2007) Erbin enhances voltage-

dependent facilitation of Cav1.3 Ca2+ channels through relief of an autoinhibitory domain in the Cav1.3 α1subunit. J. Neurosci. 27, 1374-1385.

60. Balasubramanian S., Fam S.R. and Hall R.A. (2007) GABAB receptor association with the

PDZ scaffold Mupp1 alters receptor stability and function. J. Biol. Chem. 282, 4162-4171. 61. Bough K.J., Paquet M., Paré J.-F., Hassel B., Smith Y., Hall R.A. and Dingledine R.J.

(2007) Glutamate transport in the anticonvulsant mechanism of action for a ketogenic diet. Epilepsy Res. 74, 232-236.

62. Kuwajima M., Dehoff M.H., Furuichi T., Worley P.F., Hall R.A. and Smith Y. (2007) Localization and expression of group I metabotropic receptors in the mouse globus pallidus and subthalamic nucleus: regulatory effects of MPTP treatment and constitutive Homer deletion. J. Neurosci. 27, 6249-6260.

63. Bush C.F., Jones S.V., Lyle A.N., Minneman K.P., Ressler K.J. and Hall R.A. (2007)

Specificity of olfactory receptor interactions with other G protein-coupled receptors. J. Biol. Chem. 282, 19042-19051.

64. Lee S.F., Kelly M., McAlister A., Luck S.N., Garcia E.L., Hall R.A., Robins-Browne R.M.,

Frankel G. and Hartland E.L. (2008) A C-terminal class I PDZ binding motif of EspI/NleA modulates the virulence of attaching and effacing Escherichia coli and Citrobacter rodentium. Cell. Microbiol. 10, 499-513.

65. Raju D.V., Ahern T.H., Shah D.J., Wright T.M., Standaert D.G., Hall R.A. and Smith Y.

(2008) Differential synaptic plasticity of the corticostriatal and thalamostriatal systems in MPTP-treated monkey model of parkinsonism. Eur. J. Neurosci. 27, 1647-1658.

66. Gisler S.M., Kittanakom S., Fuster D., Wong V., Bertic M., Radanovic T., Hall R.A.,

Murer H., Biber J., Markovich D., Moe O.W. and Stagljar I. (2008) Monitoring protein-protein interactions between the mammalian integral membrane transporters and PDZ-interacting partners using a modified split-ubiquitin membrane yeast two-hybrid system. Mol. Cell. Proteomics 7, 1362-1377.

67. Jang S.-W., Liu X., Chan C.-B., Weinshenker D., Hall R.A., Xiao G. and Ye K. (2009) Amitriptyline is a TrkA and TrkB receptor agonist that promotes TrkA/TrkB heterodimerization and has potent neurotrophic activity. Chem. Biol. 16, 644-656.

68. Dunham J.H., Meyer R.C., Garcia E.L. and Hall R.A. (2009) GPR37 surface expression

enhancement by N-terminal truncation or protein-protein interactions. Biochemistry 48, 10286-10297.

69. Kunkel M.T., Garcia E.L., Kajimoto T., Hall R.A. and Newton A.C. (2009) The protein

scaffold NHERF-1 interacts with PKD and controls the amplitude and duration of localized PKD activity. J. Biol. Chem. 284, 24653-24661.

70. Stalker T.J., Wu J., Morgans A., Traxler E.A., Wang L., Chatterjee M.S., Lee D.,

Quertermous T., Hall R.A., Hammer D.A., Diamond S.L. and Brass L.F. (2009) Endothelial cell specific adhesion molecule (ESAM) localizes to platelet-platelet contacts and regulates thrombus formation in vivo. J. Thromb. Haemost. 7, 1886-1896.

71. Wang B., Ardura J.A., Romero G., Yang Y., Hall R.A. and Friedman P.A. (2010)

Na+/H+ exchanger regulatory factors control parathyroid hormone receptor signaling by facilitating differential activation of Gα protein subunits. J. Biol Chem. 285, 26976-26986.

72. Martinez E., Schroeder G.N., Berger C.N., Lee S.F., Robinson K.S., Badea L., Simpson N.,

Hall R.A., Hartland E.E., Crepin V.F. and Frankel G. (2010) Binding to Na+/H+ exchanger regulatory factor 2 (NHERF2) affects trafficking and function of the enteropathogenic Escherichia coli type III secretion system effectors Map, EspI and NleH1. Cell. Microbiol., 12, 1718-1731.

73. Jiang Y., Huang Y., Wong H.-C., Zhou H., Wang X., Shukla D., Hall R.A., Brown E.M.

and Yang J.J. (2010) Elucidation of a novel extracellular calcium binding site on metabotropic glutamate receptor 1 alpha (mGluR1α) that controls receptor activation. J. Biol. Chem. 285, 33463-33474.

74. Ritter S.L., Asay M.J., Paquet M., Paavola K.P., Reiff R.E., Yun C.C. and Hall R.A. (2011)

GLAST stability and activity are regulated by interaction with the PDZ scaffold NHERF-2. Neurosci. Lett. 487, 3-7.

75. Lee S.-L., Zhang H., Ritter S.L., Shim H., Hall R.A. and Yun C.C. (2011) MAGI-3 is a

negative regulator of colon cancer that competes with NHERF-2 to regulate LPA2 signaling. Gastroenterology 140, 924-934.

76. Paavola K.J., Stephenson J.R., Alter S.P., Ritter S.L. and Hall R.A. (2011) The N terminus of the adhesion G protein-coupled receptor GPR56 controls receptor signaling activity. J. Biol. Chem. 286, 28914-28921.

77. Lin Y., Hall R.A. and Kuhar M.J. (2011) CART peptide stimulation of G protein-mediated signaling in differentiated PC12 cells: identification of PACAP 6-38 as a CART receptor antagonist. Neuropeptides 45, 351-358.

78. O'Neill A., Gallegos L., Justilien V., Garcia E.L., Leitges M., Fields A., Hall R.A. and

Newton A.C. (2011) PKCα promotes cell migration through a PDZ-dependent interaction with its novel substrate discs large homolog (DLG) 1. J. Biol. Chem. 286, 43559-4368.

79. Bogenpohl J., Ritter S.L., Hall R.A. and Smith Y. (2012) Ultrastructural localization of the

adenosine A2A receptor in the monkey basal ganglia and its subcellular colocalization with metabotropic glutamate receptor 5 in the striatum. J. Comp. Neurol. 520, 570-589.

80. Chen Y., Sheng R., Kallberg M., Silkov A., Tun M.P., Bhardwaj N., Kurilova S., Hall R.A.,

Honig, B., Lu H. and Cho W. (2012) Genome‐wide functional annotation of dual- specificity protein‐ and lipid‐binding modules that regulate protein interactions. Mol. Cell 46, 226-237.

81. Courbebaisse M., Bakouh N., Salaun C., Leroy C., Beck L., Grandchamp B., Planelles G.,

Hall R.A., Friedlander G. and Prié D. (2012) A new human NHERF1 mutation decreases renal phosphate transporter NPT2a expression by a PTH-independent mechanism. PLoS ONE 7, e34764.

82. Matsumoto M., Fujikawa A., Suzuki R., Shimizu H., Kuboyama K., Hiyama T.Y.,

Hall R.A. and Noda M. (2012) SAP97 promotes the stability of Nax channels at the plasma membrane. FEBS Lett. 586, 3805-3812.

83. Dunn H.A., Walther C., Godin C.M., Hall R.A. and Ferguson S.S.G. (2013) SAP97

interaction with the corticotropin-releasing factor receptor 1 PDZ binding motif antagonizes receptor endocytosis and promotes ERK1/2 signaling. J. Biol. Chem. 288, 15023-15034.

84. Meyer R.C., Giddens M.M., Schaefer S.A. and Hall R.A. (2013) GPR37 and GPR37L1 are

receptors for the neuroprotective and glioprotective factors prosaptide and prosaposin. Proc. Natl. Acad. Sci. USA 110, 9529-9534.

85. Stephenson J.R., Paavola K.J., Schaefer S.A., Kaur B., Van Meir E.G. and Hall R.A. (2013) Brain angiogenesis inhibitor-1 signaling, regulation and enrichment in the postsynaptic density. J. Biol. Chem. 288, 22248-22256.

86. Monteiro A.C, Sumagin R., Rankin C.R., Leoni G., Mina M.J., Reiter D.M., Stehle T.,

Dermody T.S., Schaefer S.A., Hall R.A., Nusrat A. and Parkos C.A. (2013) JAM-A associates with ZO-2, Afadin and PDZ-GEF1 to activate Rap2c and regulate epithelial barrier function. Mol. Biol. Cell 24, 2849-2860.

87. Jiang Y., Nagaraju M., Meyer R.C., Zhang L., Hamelberg D., Hall R.A., Brown E.M.,

Conn P.J. and Yang J.J. (2014) Extracellular calcium modulates actions of orthosteric and allosteric drugs on metabotropic glutamate receptor 1α. J. Biol. Chem. 289, 1649-1661.

88. Lee H.J., Kwon M.H., Lee S. Hall R.A., Yun C.C. and Choi I. (2014) Systematic family-

wide analysis of sodium bicarbonate transporter NBCn1/SLC4A7 interactions with PDZ scaffold proteins. Physiol. Rep. 2, e12016.

89. Sarma G.N., Moody I.S., Ilouz R., Phan R.H., Sankaran B., Hall R.A. and Taylor S.S.

(2015) D-AKAP2:PKA RII:PDZK1 ternary complex structure: Insights from the nucleation of a polyvalent scaffold. Protein Sci. 24, 105-116.

90. Zhu D., Li C.C., Swanson A.M., Villalba R., Guo J., Zhang Z., Matheny S., Murakami T.,

Stephenson J.R., Daniel S., Fukata M., Hall R.A., Olson J.J., Neigh G.N., Smith Y., Rainnie D.G. and Van Meir E.G. (2015) BAI1 regulates spatial learning and synaptic plasticity in the hippocampus. J. Clin. Invest. 125, 1497-1508.

91. Gaval-Cruz M., Goertz R., Puttick D., Bowles D., Meyer R., Hall R.A., Ko D., Paladini C.

and Weinshenker D. (2016) Chronic loss of noradrenergic tone produces β-arrestin2-mediated cocaine hypersensitivity and alters cellular D2 responses in the nucleus accumbens. Addiction Biol. 21, 35-48.

92. Knafo S., Sánchez-Puelles C., Palomer E., Delgado I., Draffin J.E., Mingo J., Wahle T., Kaleka K., Mou L., Pereda-Perez I., Klosi E., Faber E.B., Chapman H.M., Lozano-Montes

L., Ortega-Molina A., Ordóñez-Gutiérrez L., Wandosell F., Viña J., Dotti C.G., Hall R.A., Pulido R., Gerges N.Z., Chan A.M., Spaller M.R., Serrano M., Venero C., Esteban J.A. (2016) PTEN recruitment controls synaptic and cognitive function in Alzheimer's models. Nat. Neurosci. 19, 443-53.

93. Kishore A., Purcell R.H., Nassiri-Toosi Z. and Hall R.A. (2016) Stalk-dependent and stalk-

independent signaling by the adhesion G protein-coupled receptors GPR56 (ADGRG1) and BAI1 (ADGRB1). J. Biol. Chem. 291, 3385-3394.

Manuscripts Submitted

Robinson K.S., Mousnier A., Garcia E.L., Pearson J.S., Crepin V.F., Hemrajani C., Hall R.A., Hartland E.L., Berger C.N. and Frankel G. (2016) Bacterial effector NleH binds to the MAGUK protein SAP97/Dlg1 to block translocation of Bax to the mitochondria and apoptosis. Manuscript submitted. Kuwajima M., Dehoff M.H., Furuichi T., Worley P.F., Hall R.A. and Smith Y. (2016) Homer proteins regulate presynaptic localization of group I metabotropic glutamate receptors in the mouse globus pallidus, but not subthalamic nucleus. Manuscript submitted.

Kishore A. and Hall R.A. (2016) Versatile signaling activity of adhesion GPCRs. Manuscript submitted.

Published Review Articles & Book Chapters 1. Hall R.A., Premont R.T. and Lefkowitz R.J. (1999) Heptahelical receptor signaling:

beyond the G protein paradigm. J. Cell Biol. 145, 927-932. 2. Premont R.T. and Hall R.A. (2001) Identification of novel G protein-coupled receptor-

interacting proteins. Methods Enzymol. 343, 613-623. 3. Hall R.A. and Lefkowitz R.J. (2002) Regulation of G protein-coupled receptor signaling by

scaffold proteins. Circ. Res. 91, 672-680. 4. Hall R.A. (2004) Studying protein-protein interactions via blot overlay or far western blot.

Methods Mol. Biol. 261, 167-174. 5. Hall R.A. (2004) β-adrenergic receptors and their interacting proteins. Semin. Cell Dev.

Biol. 15, 281-288. 6. Hague C., Hall R.A. and Minneman K.P. (2004) Olfactory receptor localization and function:

an emerging role for GPCR heterodimerization. Mol. Interv. 4, 319-320. 7. Hall R.A. (2005) Co-immunoprecipitation as a strategy to evaluate receptor-receptor

or receptor-protein interactions. Chapter in Receptor Biochemistry and Methodology (John Wiley & Sons), Susan R. George and Brian F. O’Dowd, editors.

8. Prinster S.C., Hague C. and Hall R.A. (2005) Heterodimerization of G protein-coupled

receptors: specificity and physiological importance. Pharmacol. Rev. 57, 289-298. 9. Weinman E.J., Hall R.A., Friedman P.A., Liu-Chen L.-Y. and Shenolikar S. (2006) The

association of NHERF adaptor proteins with G protein-coupled receptors and receptor tyrosine kinases. Annu. Rev. Physiol. 68, 491-505.

10. Bush C.F. and Hall R.A. (2008) Olfactory receptor trafficking to the plasma membrane.

Cell. Mol. Life Sci. 65, 2289-2295. 11. Dunham J.H. and Hall R.A. (2009) Enhancement of the surface expression of G protein-

coupled receptors. Trends Biotechnol. 27, 541-545. 12. Hall R.A. (2009) Take it to heart: talking drugs, supplements and cardiovascular health

with Bob Lefkowitz. Mol. Interv. 9, 220-225. 13. Hall R.A. (2009) Olfactory receptor interactions with other receptors. Ann. N.Y. Acad. Sci.,

1170, 147-149. 14. Ritter S.L. and Hall R.A. (2009) Fine-tuning of GPCR activity by receptor-interacting

proteins. Nat. Rev. Mol. Cell Biol. 10, 819-830.

15. Hall R.A. (2011) Autonomic modulation of olfactory signaling. Sci. Signal. 4 (155), pe1. 16. Ritter S.L. and Hall R.A. (2011) Detection and characterization of receptor interactions with

PDZ domains. Methods Mol. Biol. 756, 345-356. 17. Paavola K.J. and Hall R.A. (2012) Adhesion G protein-coupled receptors: signaling,

pharmacology, and mechanisms of activation. Mol. Pharmacol. 82, 777-783. 18. Stephenson J.R., Purcell R.H. and Hall R.A. (2014) The BAI subfamily of adhesion

GPCRs: synaptic regulation and beyond. Trends Pharmacol. Sci. 35, 208-215. 19. Meyer R.C., Giddens M.M., Coleman B.M. and Hall R.A. (2014) The protective role of

prosaposin and its receptors in the nervous system. Brain Res. 1585, 1-12. 20. Liebscher I., Ackley B., Araç D., Ariestanti D.M., Aust G., Bae B.-I., Bista B.R., Bridges

J.P., Duman J.G., Engel F.B., Giera S., Goffinet A.M., Hall R.A., Hamann J., Hartmann N., Lin H.-H., Liu M., Luo R., Mogha A., Monk K., Peeters M.C., Prömel S., Ressl S., Schiöth H.B., Sigoillot S., Song H., Talbot W.S., Tall G.G., White J.P., Wolfrum U., Xu L. and Piao X. (2014) New roles and signaling mechanisms for the family of Adhesion G protein- coupled receptors Ann. N.Y. Acad. Sci. 1333, 43-64.

21. Hamann J., Aust G., Araç D., Engel F.B., Formstone C., Fredriksson R., Hall R.A., Harty

B.L., Kirchhoff C., Knapp B., Krishnan A., Liebscher I., Lin H.H., Martinelli D.C., Monk K.R., Peeters M. C., Piao X., Prömel S., Schöneberg T., Schwartz T.W., Singer K., Stacey M., Ushkaryov Y.A., Vallon M., Wolfrum U., Wright M.W., Xu L., Langenhan T., Schiöth H.B. (2015) International Union of Basic and Clinical Pharmacology. XC. Adhesion G protein-coupled receptors. Pharmacol. Rev. 67, 338-367.